⌘K
Loading ticker…
As of 2026-08-24, Pacific Biosciences of California, Inc. (PACB) has a 3-month relative strength percentile of 58 within the TickerStance CS+ADRC universe (~5,000 tickers). Its Power rating (absolute 1–99) is 46. The current market Stance is 47.8 (Neutral). Sector: Healthcare, ranked 3 of 11. Average daily range 7.7%, relative volume 0.78×. TickerStance reports observed regime conditions across the full CS+ADRC universe; band assignment reflects current breadth, momentum, and macro inputs computed at the daily close. Percentile ranks run from 1 (weakest) to 99 (strongest) relative to all universe members on the same date.
PACB is in a stage 4 downtrend, week 3. Extended from base. VCP detected: inconclusive. Distance from 50d / 200d: -8.3% / -22.5%.
Relative strength across horizons plus the leadership score.
Accumulation rating, relative volume, U/D ratio, breakout-day proof.
Diluted EPS, last 8 quarters. Loss makers are judged by progress toward breakeven.
PACB is held by 18 ETFs as of May 2026. Top owner: SCHA at 0.01% weight, $2M notional. Top 3 carry $5M.
Held by 39 ETFs · $84M across latest filings · largest weight 1.41% (ARKG).
Top 10 by value, from SEC N-PORT-P filings dated May 2026.
| ETF | Weight | Value | Δ |
|---|---|---|---|
| SCHASchwab U.S. Small-Cap ETF | 0.01% | $2M | — |
| VTWO | 0.01% | $2M | — |
| VHTVanguard Health Care ETF | 0.01% | $1M | — |
| VTWV | 0.03% | $327K | — |
| VFMO | 0.02% | $283K | −0.05 pp |
Weak relative strength and quiet attention. Little to read here either way.
Measures how unusual this name’s public attention is against its own 90-day history — a surprise reading, not a ranking of how watched it is versus other stocks. Intel, not a signal.
Daily range, ATR, beta, and the math for a 1-ADR stop.
YoY sales growth, last 8 quarters. Sales must back the earnings story.
TTM operating margin. Expansion = real operating leverage.
YoY common shares outstanding. Down = buyback tailwind. Up > 2% = dilution flag.
Reported figures from SEC filings. No analyst estimates or forward guidance.
| 0.00% |
| $260K |
| — |
| GNOM | 0.40% | $226K | +0.02 pp |
| EVNT | 0.75% | $92K | — |
| QQQS | 0.36% | $68K | +0.02 pp |
| VTHRVanguard Russell 3000 ETF | 0.00% | $34K | — |
Showing 10 of 18 ETF owners.
As filed in N-PORT — quarterly holdings with up to ~60-day publication lag. Not live positioning.
Related searches
| Jan | Feb | Mar | Apr | May | Jun | Jul | Aug | Sep | Oct | Nov | Dec | |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| 1 | PACB Jan avg: 1.74% median: 2.50% win: 50% σ: 32.00% n: 4 2022-04-12 → 2026-07-31 | PACB Feb avg: -16.17% median: -16.59% win: 0% σ: 8.20% n: 4 2022-04-12 → 2026-07-31 | PACB Mar avg: -11.18% median: -20.03% win: 25% σ: 26.46% n: 4 2022-04-12 → 2026-07-31 | PACB Apr avg: -14.54% median: -8.46% win: 20% σ: 27.94% n: 5 2022-04-12 → 2026-07-31 | PACB May avg: -1.08% median: -6.29% win: 40% σ: 13.10% n: 5 2022-04-12 → 2026-07-31 | PACB Jun avg: 0.78% median: 7.43% win: 60% σ: 22.63% n: 5 2022-04-12 → 2026-07-31 | PACB Jul avg: 8.64% median: -0.68% win: 40% σ: 25.35% n: 5 2022-04-12 → 2026-07-31 | PACB Aug avg: -4.77% median: -9.84% win: 25% σ: 28.48% n: 4 2022-04-12 → 2026-07-31 (current) | PACB Sep avg: -1.28% median: -1.61% win: 25% σ: 20.45% n: 4 2022-04-12 → 2026-07-31 | PACB Oct avg: 32.47% median: 36.52% win: 75% σ: 45.25% n: 4 2022-04-12 → 2026-07-31 | PACB Nov avg: 12.94% median: 13.26% win: 50% σ: 23.16% n: 4 2022-04-12 → 2026-07-31 | PACB Dec avg: -7.95% median: -11.79% win: 25% σ: 17.87% n: 4 2022-04-12 → 2026-07-31 |